Skip to main content
OpenTrials
Completed

NCT Number: NCT03564379

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

WCCT Global, LLC

Cypress, California, 90630, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy on the basis of clinical laboratory tests performed at screening and Day -1. If the results of the serum chemistry panel including liver enzymes, other specific tests, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
  • A man who is sexually active with a woman of childbearing potential, and has not had a vasectomy with confirmation of azoospermia, must agree to use a barrier method of birth control during the study and for 3 months after receiving the last dose of study drug, and his female partner must also use a highly effective form of birth control at least one month prior to the first study dose and continuing until 3 months after the final study dose. Acceptable barrier methods are male condoms with spermicide, and for the female partner a diaphragm or cervical cap with appropriate spermicidal foam, cream, or gel. Highly effective forms of birth control for the female partner are prescribed hormonal implants, contraceptive patches, contraceptive injections, oral contraceptives, and intrauterine device (IUD)
  • Body Mass Index (BMI; weight/height^2 [kilogram per meter square {kg/m^2}]) between 18.0 and 30.0 kg/m^2 (inclusive), and body weight not less than 50.0 kilogram (kg)
  • Blood pressure (BP) (after the participant is standing for 3 minutes, supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic (orthostatic cut-off, a fall in systolic BP of at least 20 mmHg or diastolic BP of at least 10 mmHg when a person assumes a standing position is exclusionary). If BP is out of range, up to 2 repeated assessments are permitted

Exclusion criteria

  • Clinically significant abnormal values for hematology, clinical chemistry, coagulation, or urinalysis at screening (and at admission to the study center) as deemed appropriate by the investigator
  • Known allergy, hypersensitivity, or intolerance to JNJ-42165279 or its excipients
  • Any Grade 2 laboratory toxicity
  • History of clinically significant drug and/or food allergies
  • History of epilepsy or fits or unexplained black-outs

Treatment and study plan

JNJ-42165279

Drug

25 mg JNJ-42165279 tablet will be administered orally.

Placebo

Drug

Matching placebo tablet will be administered orally.

Primary outcomes

  1. Part 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    Time frame: Screening up to Day 4

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

  2. Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    Time frame: Day -1 up to approximately 28 days

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

  3. Part 1: Plasma Concentration of JNJ-42165279

    Time frame: Up to Day 4

    Plasma concentration of JNJ-42165279 will be reported.

  4. Part 2: Plasma Concentration of JNJ-42165279

    Time frame: Up to Day 14

    Plasma concentration of JNJ-42165279 will be reported.

Secondary outcomes

  1. Part 1: Minimum Observed Fatty Acid Amide Hydrolase (FAAH) Activity in White Blood Cells (WBC) Concentration (Rmin)

    Time frame: Up to Day 4

    Rmin is the minimum observed FAAH activity in WBC concentration during a dosing interval (may or may not be the trough concentration).

  2. Part 2: Minimum Observed FAAH Activity in WBC Concentration (Rmin)

    Time frame: Day 1, Days 10 to 14 and Follow-up (approximately up to 28 days)

    Rmin is the minimum observed FAAH activity in WBC concentration during a dosing interval (may or may not be the trough concentration).

  3. Part 1: Time to Minimum Observed FAAH Activity in WBC Concentration (tmin)

    Time frame: Up to Day 4

    tmin is the time to the minimum observed FAAH activity in WBC concentration occurred during a dosing interval (may or may not be the trough concentration).

  4. Part 2: Time to Minimum Observed FAAH Activity in WBC Concentration (tmin)

    Time frame: Day 1, Days 10 to 14 and Follow-up (approximately up to 28 days)

    tmin is the time to the minimum observed FAAH activity in WBC concentration occurred during a dosing interval (may or may not be the trough concentration).

  5. Part 1: Maximum Percent Change in FAAH Activity in WBCs, Compared to Baseline (Predose) Value of Plasma Fatty Acid Amides (FAA)

    Time frame: Baseline Up to Day 4

    Maximum percent change in FAAH activity in WBCs, compared to baseline (that is, predose) value of Plasma FAA (ethanolamine [AEA], Palmitoylethanolamide/amine [PEA] and Oleoylethanolamide/amine [OEA]) will be observed.

  6. Part 2: Maximum Percent Change in FAAH Activity in WBCs, Compared to Baseline (Predose) Value of Plasma FAA

    Time frame: Baseline, Day 1, Days 10 to 14 and Follow-up (approximately up to 28 days)

    Maximum percent change in FAAH activity in WBCs, compared to baseline (that is, predose) value of Plasma FAA (AEA, PEA, and OEA) will be observed.

  7. Part 1: Plasma Concentrations of Fatty Acid Amides (FAAs - N-Arachidonoyl ethanolamine [AEA], Palmitoylethanolamide/amine [PEA] and Oleoylethanolamide/amine [OEA])

    Time frame: Up to Day 3

    Plasma concentration of FAAs including AEA, PEA, and OEA will be reported.

  8. Part 2: Plasma Concentrations of FAAs (AEA, PEA and OEA)

    Time frame: Day 1 and Days 10 to 14

    Plasma concentration of FAAs including AEA, PEA, and OEA will be reported.

Sponsors and collaborators

Lead sponsor

Janssen Research & Development, LLC

Industry

Registry information

Official study title

A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Subjects

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Jun 20, 2018
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.